Rarely: <0.1%; infrequently: 0.1% to <5%; no specific designation: 5%; frequency unknown.
Clinically Significant Adverse Reactions: Hypoglycemia:
Hypoglycemia may occur. If the patient develops hypoglycemia, glucose should be administered promptly by intravenous infusion. In addition, appropriate nutrition management is required in such patients.
Hyperammonemia has been reported. If the patient develops persistent hyperammonemia during the administration of Aminoleban, discontinue administration and take measures to eliminate other nitrogen sources.
Other Adverse Reactions: Hypersensitivity:
Symptoms eg, skin rash may occur rarely. In the event of skin rash, discontinue the administration and institute appropriate treatment.
Symptoms eg, nausea and vomiting may occur infrequently.
Symptoms eg, chest discomfort and palpitation may occur infrequently.
The nitrogen content of this preparation may induce a transient increase in blood ammonia concentrations.
Large Dose and Rapid Administration:
Acidosis may occur when large doses are administered rapidly.
Chills, fever, headache and vascular pain may infrequently occur.